VectorialDATA

KO — The Coca-Cola Company

Consumer DefensiveNorth AmericaUnited StatesBlockchain certified

Price when we picked it (Jul 16, 2026)

$83.50

Target: $87.10 (+4.3%)

P/E Ratio

26.7

P/E Forward

24.4

Dividend

2.57%

Market Cap

$365.4B

EPS

$3.18

Consensus

Buy

What they do

Coca-Cola makes money on something smarter than bottling soda: it sells the concentrate (the secret syrup) to a worldwide network of independent bottlers, who are the ones putting up the factories, the trucks, and the heavy costs. Coca-Cola provides the brand, the formula, and the marketing; the bottler provides the hardware. That's why its margins are out of this world: in the last quarter, out of every $100 it sold, $35 was operating profit.

Its portfolio goes far beyond red-can Coca-Cola:

  • Sodas: Coca-Cola, Coca-Cola Zero Sugar (growing 13-14% a year), Sprite, Fanta.
  • Dairy and protein: fairlife, the ultra-filtered high-protein milk that's its fastest-growing brand in the US — demand is so strong it's opening a $650 million plant in New York, the largest in the country's Northeast.
  • Hydration and sports: Powerade, BodyArmor, smartwater, Topo Chico.
  • Coffee and tea: Costa Coffee, Fuze Tea, Gold Peak.
  • Juices: Del Valle, Minute Maid, Simply.

All told, that's about 200 brands in more than 200 countries, roughly 65,900 direct employees (and about 700,000 counting the system's bottlers). It is, literally, the largest beverage distribution machine that exists.

Why we like it

1. Last quarter was excellent. In Q1 2026, revenue grew 12% to $12.5 billion, and organic growth (stripping out currency effects and business acquisitions/sales) was 10%. Volume rose 3% — people aren't just paying more, they're buying more too — and the operating margin reached 35%, better than a year ago. Earnings per share grew 18%. North America grew volume 4% with operating profit up 20%.

2. This is the most reliable dividend in the market. In February 2026 it raised the dividend for the 64th consecutive year — going back to 1962, without missing a single one, through wars, oil crises, 2008, and the pandemic. It now pays $2.12 per share a year (2.57% at this price), and there's still room to grow: the company expects to generate roughly $12.2 billion in cash coming in during 2026.

3. The Buffett seal of approval. Berkshire Hathaway has held exactly 400 million shares since August 1994 — more than 30 years without selling a single one. In dividends alone, Coca-Cola will pay Berkshire around $848 million this year. It's one of Buffett's 3 largest positions.

4. The growth engines are real. Coca-Cola Zero Sugar grew 14% in volume in 2025 and 13% in Q1 2026 — the direct answer to consumers who want less sugar. And fairlife (high-protein milk) has demand at all-time highs; the new $650 million plant in Webster, NY opens this year to produce more.

5. It's the anchor this portfolio needs. We just bought several tech and semiconductor names — stocks that can swing up or down 30% in a year. Coca-Cola moves with roughly a third of the market's big price swings, and it's up 18% in 2026, beating both the S&P 500 and the Nasdaq. 2026 guidance: 4-5% organic growth and earnings per share up 8-9%. It's not a rocket ship; it's the ballast that keeps the boat steady — and this year, that ballast happens to be running too.

Key Risk

1. The price is no longer a bargain. The stock is at an all-time high (it hit $85.68 on July 7) and trades at 26.7 times its profit — expensive for a company growing 4-5% organically. Analysts' average price target is $87.10: only about 4% above our $83.50. If the market stops paying a premium for defensive stocks, the shares could stay flat for years even if the business keeps performing.

2. The world is drinking less sugar. Weight-loss drugs (like Ozempic) and shifting habits are reducing sugary soda consumption in developed countries. For now, Coca-Cola Zero Sugar (+13%) and fairlife more than make up for it, but it's a permanent headwind.

3. The next earnings report (July 28) could disappoint. Last quarter was partly inflated by 6 extra calendar days in concentrate shipments; that effect reverses in Q2, and analysts have already trimmed their estimates. Buying 12 days before the report carries that risk.

4. Currencies. More than 60% of sales come from outside the US; a strong dollar hits profits directly (right now the wind is at its back, but that can change).

5. Not everything it buys works out. BodyArmor has already racked up $1.7 billion in write-downs since it was acquired — a reminder that even Coca-Cola gets it wrong sometimes.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked KO on Jul 16, 2026 at $83.50.

Full Research

What it is

The Coca-Cola Company (NYSE: KO) is the world's largest beverage company. Founded in 1886 in Atlanta, Georgia — still its headquarters today — it now sells about 200 brands in more than 200 countries and territories: more than 2.2 billion servings of its products are consumed every day. It has roughly 65,900 direct employees (per the 10-K as of December 2025; the drop versus prior years is due to bottling business divestitures), and the full «Coca-Cola system» — the company plus its bottlers — employs about 700,000 people, one of the largest private employers on the planet.

Since March 31, 2026, the CEO has been Henrique Braun, a Brazilian with 30 years inside the company, who replaced James Quincey (now executive chairman of the board) in an orderly succession announced months in advance. Total continuity of strategy.

How it makes money

The secret of the business isn't bottling — it's selling the concentrate. Coca-Cola makes the syrup and sells it to hundreds of independent bottlers around the world (Coca-Cola FEMSA in Latin America, Coca-Cola Europacific Partners in Europe, etc.). The bottlers put up the plants, the trucks, the coolers, and the labor — the heavy capital and the low margins. Coca-Cola provides the brand, the formula, and the marketing — the light capital and the high margins.

The result: in Q1 2026 the operating margin was 35.0% (34.5% on a comparable basis). Out of every $100 sold, $35 is operating profit. PepsiCo, which does own much of its production and also sells snacks, operates with far lower margins.

The portfolio breaks down into categories: sodas (Coca-Cola, Sprite, Fanta), zero sugar (Coca-Cola Zero Sugar), hydration and sports (smartwater, Powerade, BodyArmor, Topo Chico), dairy and protein (fairlife, Santa Clara), juices (Del Valle, Minute Maid, Simply), and coffee/tea (Costa Coffee, Fuze Tea). The strategy since 2020: fewer, bigger brands, and «a drink for every occasion» — if you drop the soda, they want you switching to a water, a tea, or a protein milk that's also theirs.

The numbers: last quarter and the full year

Q1 2026 (reported April 2026) — an outstanding quarter:

  • Revenue: $12.5 billion, +12%.
  • Organic growth: +10% (concentrate sales +8%, price/mix +2%).
  • Unit case volume: +3% — real growth, not just price.
  • GAAP operating margin: 35.0% (vs. 32.9% a year earlier).
  • Comparable earnings per share: $0.86, +18%.
  • By region: North America volume +4% with operating profit +20%; EMEA price/mix +5% with profit +18%; Latin America profit +15%. The weak spot: Asia Pacific, with price/mix -6% and operating profit -14%.
  • Coca-Cola Zero Sugar: +13% in volume, growing in every region.
  • Important note: concentrate sales outpaced volume by 5 points, largely due to 6 extra calendar days in the quarter. That effect reverses in Q2 (see risks).

After this quarter, the company raised its 2026 guidance: organic growth of 4% to 5%, comparable earnings per share up 8% to 9%, and free cash flow (cash coming in) of about $12.2 billion.

Full year 2025: revenue of $47.9 billion (+2%), organic growth +5% (price/mix +4%, concentrate +1%). Coca-Cola Zero Sugar grew 14% in volume for the year. Adjusted free cash flow: $11.4 billion (excluding a one-time $6.1 billion payment to fairlife's former owners — the final payout of an acquisition that turned out so well the agreed «performance bonus» hit its maximum). The blemish of the year: a $960 million write-down on the BodyArmor brand in Q4 ($1.7 billion accumulated since the acquisition).

The thesis

First: it's the most reliable dividend in the market. In February 2026, the board approved the 64th consecutive annual dividend increase: from $0.51 to $0.53 quarterly (+3.9%), or $2.12 a year. Since 1962, Coca-Cola has raised its dividend every single year without exception — through the Vietnam War, two oil crises, 1980s inflation, the 2008 crisis, and the pandemic. Only a handful of companies in the world have a track record like this (companies with 50+ years are called «Dividend Kings»; Coca-Cola has 64). At $83.50, the dividend (the cash they pay you) is 2.57% — nearly double the S&P 500 — with a payout of about 67% of earnings and plenty of cash coming in to keep raising it.

Second: the Buffett seal of approval. Berkshire Hathaway has owned exactly 400 million shares since August 1994 — more than 30 years without selling or buying a single one. It's one of Buffett's 3 largest positions (roughly $31-33 billion as of mid-2026). With the new dividend, Berkshire will collect about $848 million in 2026 for doing absolutely nothing. Its original investment was about $1.3 billion — today it collects roughly 65% of that entire amount every single year, just in dividends.

Third: the growth engines are real, not a story. (a) Coca-Cola Zero Sugar grew 14% in 2025 and 13% in Q1 2026 — the masterstroke against sugar-averse consumers: if you drop the red can, you stay in the black-can family. (b) fairlife, the ultra-filtered high-protein milk, is the most impressive growth story in US consumer goods: demand is at all-time highs and the limiting factor is production capacity, not appetite. That's why this year it's opening the $650 million plant in Webster, New York: 745,000 square feet, the largest dairy plant in the US Northeast, processing 5-6 million pounds of milk a day. (c) The GLP-1 phenomenon (Ozempic and similar drugs), which scares snack and alcohol makers, hits Coca-Cola less: protein (fairlife), zero calories (Zero Sugar), and hydration are exactly what that consumer is looking for.

Fourth: it's the perfect counterweight to this portfolio. This batch of buys is loaded with tech and semiconductor names — brilliant businesses but ones with big price swings. Coca-Cola has a five-year beta of about 0.35: it moves with roughly a third of the market's big price swings. And it isn't sacrificing returns for safety: in 2026 the stock is up about 18%, beating both the S&P 500 and the Nasdaq-100, driven by the rotation into defensive names and its own stellar Q1 report. The consensus of 24 analysts is Buy, with an average price target of $87.10.

Valuation

Here's the catch. At $83.50:

  • Trailing price vs. profit: 26.7x (earnings per share of $3.18 over the last 12 months).
  • Forward price vs. profit: 24.4x.
  • Market cap: $365.4 billion.
  • Dividend: 2.57%.
  • Average price target: $87.10 — only about 4.3% above.

Paying 26.7 times profit for a business growing 4-5% organically isn't cheap; it's the premium the market has always paid for extreme quality, and today it's toward the high end of its historical range because the stock is in fashion as a safe haven. A reasonable expected return is: earnings growth (8-9%) plus dividend (2.6%), minus possible multiple compression. In other words: a normal year should deliver a high single digit, not a Nvidia-style 2019. You buy this for the stability and the growing dividend, not for explosive upside.

Risks

1. Valuation at highs

The stock hit its all-time high ($85.68) on July 7, 2026, and trades at 26.7x profit. The average price target ($87.10) leaves about 4% of room. If the rotation into defensive stocks reverses — for example, if borrowing costs fall and money flows back into growth — the multiple could compress and the stock could sit flat for years even if the business delivers. This is risk #1, and it isn't small: paying a high price for quality is still paying a high price.

2. The structural decline of sugary soda

In developed markets, sugary soda consumption has been falling for years, and GLP-1 drugs (Ozempic, Wegovy) are speeding up the shift in habits. Today, Zero Sugar (+13%) and fairlife more than make up for it, but it's a headwind that will never fully go away.

3. A letdown on July 28

Coca-Cola reports Q2 2026 in 12 days. Q1's +10% organic growth was inflated by 6 extra calendar days in concentrate shipments; that effect reverses now, and analysts like Jefferies are already modeling barely about 1.6% growth in concentrate sales for Q2. If the market was expecting another 10% quarter, there could be a jolt — though the full-year guidance of 4-5% already accounts for this.

4. Currencies

More than 60% of sales come from outside the US. Right now the company expects a 1-2% currency tailwind in 2026, but that can flip fast: a strong dollar in 2022-2024 cost it several points of growth. It's a permanent risk of the global model.

5. Deals that don't pan out

BodyArmor, bought in 2021 for $5.6 billion, has already racked up $1.7 billion in write-downs ($960 million in Q4 2025 alone). fairlife was a home run; BodyArmor has been a stumble. Capital deployed into acquisitions doesn't always pay off.

6. Weakness in Asia Pacific

In Q1 2026 the region had price/mix of -6% and operating profit of -14%. India and China are key to volume growth over the coming decades; if the weakness persists, the 4-5% organic growth target becomes harder to hit.

7. Regulation and sugar taxes

More and more countries are applying taxes on sugary drinks, and scrutiny of sweeteners (like the aspartame in Zero Sugar, which the WHO classified in 2023 as «possibly carcinogenic» while keeping safe consumption levels unchanged) generates periodic headlines. So far the company has navigated all of this by reformulating and raising prices, but the regulatory risk never fully disappears.

Verdict

Coca-Cola at $83.50 is exactly what it looks like: the portfolio's anchor. The business is at its best in years — Q1 with +10% organic growth, a 35% margin, and earnings up 18%, raised guidance, fairlife opening new capacity, Zero Sugar flying — the dividend just marked 64 consecutive years of increases, and Buffett still hasn't sold a share after three decades. This isn't bought expecting to double your money: at 26.7x profit and with the price target only 4% away, the expected return is the dividend (2.57%) plus earnings growth (8-9%), with the big price swings of a well-behaved bond. In a batch full of semiconductors, this is the position that lets you sleep easy — and, as a bonus, it's beating the Nasdaq in 2026.

More picks in Consumer Defensive

See all Consumer Defensive picks →

More picks from United States

See all picks from United States →
Researched: Jul 16, 2026Updated: Jul 16, 2026Next review: Jan 16, 2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.